Poseida Therapeutics To Be Acquired BB Roche In $1.5B Deal, Stockholders To Receive Up To $13/ Share In Cash
Poseida Therapeutics To Be Acquired BB Roche In $1.5B Deal, Stockholders To Receive Up To $13/ Share In Cash
poseida therapeutics 將被羅氏以15億的交易收購，股東將獲得最高13美元/股的現金。
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion
Poseida股東將收到每股高達13.00美元現金，包括每股9.00美元現金在交易完成時和一個非可交易的權益部分（CVR），可獲得每股高達4.00美元的現金；交易代表了高達15億美元的總資產價值
Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals
Poseida將加入Roche集團，並作爲Roche製藥部門的一部分，推進其創新的非病毒TSCm豐富的CAR-T療法和遺傳藥物的管線
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間